



## **Imaxio sells its genomics division to Hybrigenics to focus on its immunology business**

### **Imaxio will develop its IMX313 antigen re-engineering technology**

**Lyon, France – October 16, 2013** – Imaxio, a biopharmaceutical company specializing in vaccines announces today the sale of its genomics division. The buyer is Hybrigenics, a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris. The financial terms of the agreement were not disclosed.

This sale will enable Imaxio to focus more on its immunology R&D operations. The work is based on proprietary IMX313 antigen re-engineering technology, which aims to create a significant improvement in the immunogenicity and therefore the effectiveness of each vaccine in which it is used.

“There is a major need to improve the efficacy of vaccine candidates in human and animal health. We will rise to this challenge by focusing on the development of our IMX313 technology,” said Alexandre le Vert, Chief Executive Officer of Imaxio. “IMX313 may resolve the problems of developing vaccines and immunotherapies for key therapeutic indications such as tuberculosis, staphylococcal infection, influenza and malaria.”

Imaxio recently initiated a Phase 1 clinical trial of IMX313 in tuberculosis, and is one of the coordinators of the EU-funded Bellerophon project, to develop a vaccine against *Staphylococcus aureus*.

In France, Imaxio already markets Spirolept®, a human vaccine indicated for preventing a work-related infectious disease, and Trolovol®, an orphan drug indicated for a congenital metabolic disease. These core biopharmaceutical products generated revenue of EUR 2.1 million in 2012, providing significant financial support for the continuation of R&D activity.

#### **About Imaxio SA**

Imaxio SA is a biopharmaceutical company specializing in the area of vaccines.

Using IMX313, its antigen re-engineering technology, Imaxio is developing, both individually and with its partners, recombinant vaccines with improved effectiveness for applications in both human and animal health.

In France, Imaxio already markets Spirolept®, a human vaccine indicated for preventing a work-related infectious disease, and Trolovol®, an orphan drug indicated for a congenital metabolic disease.

Imaxio was developed from Avidis, a spin-off from the Medical Research Council and Cambridge University (UK) created in 2000. The company owns well-founded intellectual property and collaborates with numerous academic partners, including the Jenner Institute at Oxford University.

Imaxio SA is based in Lyon (France). It has 21 employees, ten of whom are engaged in R&D. In 2012 it delivered a turnover of EUR 2.7 million.

For more information, go to: <http://www.imaxio.com>

---

#### **For further information, please contact:**

Andrew Lloyd and Associates  
Sarah Morgan / Céline Gonzalez

[sarah@ala.com](mailto:sarah@ala.com) / [celine@ala.com](mailto:celine@ala.com)

Tel: +44 1273 675100

US: +1 617 517 0146

---